Healthcare Experts view on Comprehensive Genomic Profiling

March 17, 2020

Healthcare experts worldwide discuss how Comprehensive Genomic Profiling (CGP) can lead to more efficiencies in a pathology lab operation, as well as increase the likelihood of finding an actionable biomarker for every patient sample, leading to better therapeutic alternatives and outcomes. CGP enables pathology labs to consolidate independent biomarker tests into a single test, using a minimal amount of sample, thus helping the lab simplify their operation and save precious sample specimen. Furthermore, CGP enables all biomarkers in guidelines and clinical trials to be assessed in a single test, thus increasing the chances of finding a positive biomarker for therapy or clinical trial.

Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

*Data calculations on file. Illumina, Inc., 2015.

View customer spotlight videos
youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79

View Illumina webinars
youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ

View Illumina product videos
youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd

View Illumina support videos
youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

Share this article on